PDCD1 and non-small cell lung carcinoma: Programmed cell death-1 (PD-1)/programmed cell death 1 ligand 1(PD-L1) inhibitor antibodies can effectively improve the 5-year survival rate and overall survival of advanced NSCLC (22, 23).